Pfizer (PFE) Announces FDA Approval of XELJANZ for the Treatment of Active Ankylosing Spondylitis

Codexis (CDXS) Has Upside on Pfizer (PFE) COVID-19 Pill Success - Analyst

December 14, 2021 9:27 AM EST

Positive data today on Pfizer's (NYSE: PFE) COVID-19 pill is seen as bullish for Codexis (NASDAQ: CDXS).

Craig Hallum analyst Matt Hewitt notes the drug is already being manufactured using enzymes from Codexis, which creates the potential for upside in FY22.

... More

Pfizer says COVID-19 pill near 90% protective against hospitalization, death

December 14, 2021 6:54 AM EST

By Michael Erman and Deena Beasley

NEW YORK (Reuters) -Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.

The U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo, based on interim results in around 1,200 people. Data from its final analysis of the trial disclosed on Tuesday includes an additional 1,000 people.

Nobody in the trial... More

Pfizer (PFE) PT Raised to $56 at Mizuho Securities

December 14, 2021 6:46 AM EST

Mizuho Securities analyst Vamil Divan raised the price target on Pfizer (NYSE: PFE) to $56.00 (from $44.00) while maintaining a Neutral rating.... More

Pfizer (PFE) says antiviral for covid significantly reduced risk of hospitalization or death

December 14, 2021 6:45 AM EST

(Updated - December 14, 2021 6:48 AM EST)

Pfizer Inc. (NYSE: PFE) today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for... More

Pfizer-BioNTech's COVID-19 Vaccine Giving 70% Protection Against Omicron, South Africa's Private Health Insurer Says

December 14, 2021 4:51 AM EST

Two doses of COVID-19 vaccine produced by BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) give 70% protection against the emerging Omicron variant, according to South Africa's largest private health insurance company Discovery Health.

The latest data is... More

UBS Upgrades Pfizer (PFE) to Buy, Downgrades Merck (MRK) to Neutral

December 13, 2021 9:51 AM EST

UBS analyst Colin Bristow downgraded shares of Merck to Neutral (NYSE: MRK) on the lack of evident catalysts and the lack of visibility around key growth drivers.

The analyst also lowered the price target to $76.00 per share from the prior $98.00 as two key growth drivers - islatravir for HIV, molnupiravir for COVID - facilitated negative updates recentl

molnup's hospitalization/death relative risk reduction dropped from 48% (at interim) to ~30% (all evaluable patients) and... More

Pfizer’s (PFE) $6.7B Arena Acquisition is Priced Reasonably, May Offer Additional Upside, Pfizer Making Good Use of Cash – Analyst

December 13, 2021 9:30 AM EST

Earlier today, Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately... More

Pre-Open Stock Movers 12/13: (ARNA) (FHTX) (HOG) Higher; (NISN) (TXMD) (AMPE) Lower (more...)

December 13, 2021 9:21 AM EST

Pre-Open Stock Movers

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) 86.7% HIGHER; Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7... More

Low Valuations to Drive Pharma M&A in 2022 - Analyst

December 13, 2021 8:50 AM EST

In light of recently announced major biotech acquisitions - Dicerna (NASDAQ: DRNA) was acquired by Novo Nordisk (NYSE: NVO) for $38 (~80% premium) and Arena (NASDAQ: ARNA) now being acquired for $100/sh (~100% premium) by Pfizer... More

Pfizer (PFE) to Buy Arena Pharmaceuticals (ARNA) in a $6.7 Billion Deal, Pays a 100% Premium; Seen as the First of Many Acquisitions

December 13, 2021 6:41 AM EST

Pfizer (NYSE: PFE) shares are up 2% in pre-open Monday after the company announced a deal to buy Arena Pharmaceuticals (Nasdaq: ARNA) in a $6.7 billion deal.

Pfizer will pay $100 per share in an all-cash transaction, which is a 100% premium compared to Fridays closing price of $49.94 per share.

Arena is a clinical-stage... More

Pfizer bets on Arena's promising bowel disease treatment in $6.7 billion deal

December 13, 2021 6:33 AM EST

By Mrinalika Roy and Leroy Leo

(Reuters) - Pfizer Inc said on Monday it would buy drug developer Arena Pharmaceuticals Inc for $6.7 billion in cash, to add a promising treatment candidate that targets diseases affecting the stomach and intestine.

The $100 per share offer is double the last closing price of Arena's stock, which surged 83.7% to $91.92 in early trading.

This is the latest deal Pfizer has struck this year to expand its treatment pipeline. The... More